PRODIGE 22-ECKINOXE : Randomized Phase II Trial of Neoadjuvant FOLFOX 4 Versus FOLFOX 4 With Cetuximab Versus Immediate Surgery in Locally Advanced Colon Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
Indications Adenocarcinoma; Colon cancer
Focus Therapeutic Use
Acronyms ECKINOXE; PRODIGE 22; PRODIGE 22-ECKINOXE

31 May 2020 At interim analysis, the FOLFOX-cetuximab arm was stopped for futility, according to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
17 Oct 2017 Status changed from recruiting to active, no longer recruiting, according to results presented at the 42nd European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com